智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据 2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制 股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年12月31 日，董事會及╱或董事會薪酬委員會根據2016期權及激勵計劃的條款向一百五十 五名承授人授出涉及合共53,322股美國存託股份的受限制股份單位。 受限制股份單位詳情如下： 授出日期： 2025年12月31日 2016期權及激勵計劃項下的受限制股份單位 承授人數目： 一百五十五名（包括一名服務提供者，其根據聘任就 本集團主要業務有關或附屬領域向本集團提供科學 諮詢服務，以幫助維持或提高本集團的競爭力） 於2025年12月31日，董事會及╱或董事會薪酬委員會根據2016期權及激勵計劃 的條款授予一百五十五名承授人合共53,322股美國存託股份受限制股份單位。該 等受限制股份單位相當 ...

来源：环球网 "索托克拉在中国加速获批并实现全球首发，无疑是百济神州血液学产品管线进展的重要里程碑，标志 着我们的又一款自研药物将正式开始帮助患者，也进一步印证了百济神州在B细胞恶性肿瘤治疗领域的 引领性。"百济神州总裁、全球研发负责人汪来博士表示，"索托克拉在中国从受理至获批仅用时8个 月，此得益于索托克拉在研究中展现出深度且持久的缓解获益与良好的安全性，展示出其具备成为同类 最佳BCL2抑制剂的潜力，另外也反映出中国血液肿瘤患者出现耐药后的迫切治疗需求已被重视。我们 还在进一步探索索托克拉的潜力，以期帮助到全球更多患者。" 1月6日，百济神州宣布，旗下新一代BCL2抑制剂索托克拉片（百悦达®）获得国家药品监督管理局 （NMPA）附条件批准上市，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶（BTK）抑制剂在内的一 种系统治疗的慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者，以及既往接受过至少 两种系统性治疗（含布鲁顿酪氨酸激酶[BTK]抑制剂）的复发或难治性套细胞淋巴瘤（MCL）成人患 者。此前，这两项适应症的上市申请已被NMPA药品审评中心（CDE）纳入优先审评程序。 据悉，索托克拉此次以 ...

Group 1 - The A-share market experienced narrow fluctuations on January 7, with coal, chips, and innovative drug sectors leading in gains. The Southern Innovative Drug ETF (159858.SZ) rose by 1.60%, and Baijie Shenzhou increased by 3.29% [1] - The Chinese innovative drug industry is expected to undergo a value return and structural reshaping by 2025, with a shift in core logic towards product strength, platform capability, and global operational ability [1] - Policies are transitioning from encouraging innovation to a new phase of systematic and precise guidance, providing institutional support for original innovation [1] Group 2 - Capital is concentrating on companies with core technology platforms, clear clinical value, and global potential, favoring mid-to-late-stage projects in areas such as ADC, bispecific antibodies, CGT, and AI drug development [1] - The transaction amount for innovative drugs going overseas has reached a historical high, with deepening collaboration models [1] - Domestic ADC and bispecific antibody products have been approved and show globally leading data, while breakthroughs have been made in small molecule drugs targeting "undruggable" targets, and significant progress has been observed in cell therapies and nucleic acid drugs [1] Group 3 - The industry is transitioning from following innovation to original innovation, and from technology input to systematic output [1] - The trend for the innovative drug industry is positive, with strengthened global competitiveness, ongoing international expansion, and gradual realization of commercial profitability [1] - The medical device industry is experiencing a calming of influencing factors, with accelerated innovation and internationalization [1] Group 4 - The innovative drug industry is showing enhanced innovation vitality and significant internationalization results, with sufficient long-term development momentum [1] - The Southern Innovative Drug ETF (159858.SZ) can focus on innovative drugs and the industry chain, sharing the growth dividends of truly competitive companies amid industry differentiation and seizing opportunities for value reshaping [1]

Group 1: Market Performance - Hong Kong's innovative drug ETF (159570) surged by 3%, with a trading volume exceeding 1.5 billion yuan, following a net inflow of over 62 million yuan today after a previous inflow of 430 million yuan [1][3] - As of January 6, the latest scale of the Hong Kong innovative drug ETF reached over 23.3 billion yuan, leading its peers in the same category [1] Group 2: Economic Signals - Federal Reserve Governor Milan indicated that upcoming economic data may support further interest rate cuts, with expectations of a reduction exceeding 100 basis points this year [3] - Wall Street analysts suggest that if the U.S. unemployment rate rises to 4.7% by December 2025, the Fed may cut rates by 25 basis points this month [3] Group 3: Company Developments - Brain-computer interface "unicorn" Strong Brain Technology completed a financing round of 2 billion yuan, second only to Musk's Neuralink [3] - AI pharmaceutical company Insilico Medicine announced a long-term collaboration with Siveya for anti-tumor drug development, with a total deal value of 888 million USD [3] Group 4: New Drug Approvals - On January 6, BeiGene announced that its self-developed BCL2 inhibitor, Baiyueda® (sotucumab), received conditional approval from the National Medical Products Administration [3] - Shiyao's SYS6017 has initiated Phase II clinical trials for the prevention of shingles [3] Group 5: Investment Insights - Zhongtai Securities predicts that the pharmaceutical sector's opportunities in 2025 will focus on innovation and industry upgrades, with investment strategies continuing into 2026 [5] - The report emphasizes the importance of "innovative drugs and industry chains, demand recovery, and AI" as key investment dimensions [5] Group 6: J.P. Morgan Healthcare Conference - The 44th J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [6] - The conference will feature over 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6] Group 7: Industry Trends - Three major trends are highlighted for 2026: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces [7] - The report notes that over 20 gene editing companies will showcase breakthroughs in CAR-T and base editing at the conference [7] Group 8: MNC Engagement - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs from China, with the average total package for drugs purchased from China being 2.76 billion USD, compared to 1.29 billion USD for those from overseas [8] - The willingness of MNCs to pay a premium for Chinese innovations is driven by the need to fill significant pipeline gaps due to impending patent expirations [8] Group 9: Investment Focus - Investment strategies should focus on companies with strong clinical development capabilities and those in popular therapeutic areas such as ADCs, GLP-1, and dual antibodies [11] - Companies that can produce high-quality late-stage clinical assets are likely to attract MNC interest [11] Group 10: Key Therapeutic Areas - The report identifies key therapeutic areas for investment, including ADCs, GLP-1, dual antibodies, and neuroscience, emphasizing the need for innovative platforms and clinical data superiority [12]

Core Viewpoint - The approval of the BCL-2 inhibitor Sotorakra by BeiGene marks a significant advancement in the treatment of hematologic malignancies, with potential implications for the competitive landscape of BCL-2 inhibitors in the market [1][3]. Company Developments - BeiGene's Sotorakra has received approval for two indications: treatment of adult patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL) [1]. - The approval came just eight months after the new drug application was accepted by the NMPA, indicating a rapid development timeline [1]. - Sotorakra is positioned as a next-generation BCL-2 inhibitor, designed to block the BCL-2 protein that aids tumor cell survival, and has shown strong efficacy and specificity in clinical trials [1][2]. Clinical Trial Results - Early clinical trials of Sotorakra combined with Zebutini have demonstrated unprecedented rates of undetectable minimal residual disease in treatment-naive CLL patients [2]. - Recent data from five clinical studies indicate significant clinical benefits for Sotorakra, suggesting its potential as a cornerstone therapy for various B-cell malignancies [2]. Market Landscape - The global BCL-2 inhibitor market is projected to reach $5.2 billion by 2028, with the Chinese market expected to reach 1.4 billion yuan [5]. - The approval of Sotorakra follows the approval of another BCL-2 inhibitor, Lisatoclax, from Ascentage Pharma, indicating a growing presence of Chinese companies in the BCL-2 space [3][5]. - The competitive landscape is intensifying as multiple Chinese pharmaceutical companies, including Innovent Biologics and Zai Lab, are developing BCL-2 inhibitors [3][4]. Financial Performance - BeiGene's Zebutini has become a significant revenue driver, with global sales reaching $1.3 billion in 2023, marking a 129% year-over-year increase [6]. - In the first half of 2025, BeiGene reported a revenue of 17.52 billion yuan, a 46% increase year-over-year, largely driven by Zebutini sales [6][7]. - The company is under pressure to identify the next blockbuster product as Zebutini's growth may slow down in the future [7].

Core Viewpoint - BeiGene (6160.HK) announced that its self-developed first-in-class BCL2 inhibitor, Baiyueda® (Sotukral tablets), has received conditional approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received at least one systemic treatment including a Bruton tyrosine kinase (BTK) inhibitor, as well as for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two systemic treatments including a BTK inhibitor [1] Group 1 - The approval of Sotukral provides a new treatment option for CLL/SLL patients who have previously been treated with BTK inhibitors [1] - Sotukral becomes the first and only BCL2 inhibitor approved for the treatment of MCL in China [1] - The applications for these indications were previously included in the priority review process by the NMPA's Center for Drug Evaluation (CDE) [1]

Core Viewpoint - BeiGene announced that its self-developed first-in-class BCL2 inhibitor, Baiyueda® (Sotoclisib), has received conditional approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor, as well as for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two systemic therapies including a BTK inhibitor [1] Group 1 - The approval of Sotoclisib provides a new treatment option for CLL/SLL patients who have previously been treated with BTK inhibitors [1] - Sotoclisib becomes the first and only BCL2 inhibitor approved for the treatment of MCL in China [1] - The applications for these indications were previously included in the priority review process by the NMPA's Center for Drug Evaluation (CDE) [1]

2025年12月份收益率表现 从此前公布的最新季报看，宝盈医疗健康沪港深股票在去年三季度前十大重仓股为信达生物、科伦 博泰生物、百利天恒、三生制药、诺诚健华、百济神州、恒瑞医药、康方生物、信立泰、康弘药业。宝 盈创新医疗混合发起式的前十大重仓股为百利天恒、科伦博泰生物、信达生物、三生制药、康方生物、 诺诚健华、康弘药业、信立泰、石药集团、一品红。 对比来看，不仅其中有八只重仓股都相同，而且多只个股都在去年12月里遭遇了大幅下跌，如第一 大重仓股信达生物在当月下跌18.97%，三生制药更是下跌超过22%。 | 名称 | | 复权单位净值增长率% 累计单位净值元 规模 亿元 基金经理 | | | | --- | --- | --- | --- | --- | | 宝盈创新医疗混合发起式C | -14.19 | 0. 8857 | 0. 51 | 姚艺 | | 宝盈创新医疗混合发起式A | -14.14 | 0. 8886 | 0. 47 | 姚艺 | | 宝盈医疗健康沪港深股票C | -13.26 | 1.8650 | 8.29 | 姚艺 | | 宝盈医疗健康沪港深股票A | -13.20 | 1.9630 | ...

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown a positive performance since its inception, with a slight increase in scale and significant trading activity in the early days of 2024 [1][2] Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159567) closed at a 0.38% increase on January 6, with a trading volume of 1.163 billion yuan [1] - As of January 5, the fund's latest share count was 10.479 billion shares, with a total scale of 8.331 billion yuan, reflecting a 5.50% increase in scale since December 31, 2025 [1] - The fund's management fee is set at 0.50% annually, and the custody fee is 0.10% annually [1] Group 2: Trading Activity - Over the past 20 trading days, the cumulative trading amount for the ETF reached 16.464 billion yuan, with an average daily trading amount of 0.823 billion yuan [1] - In the first two trading days of 2024, the ETF recorded a cumulative trading amount of 2.789 billion yuan, averaging 1.394 billion yuan per day [1] Group 3: Fund Holdings - The top holdings of the Hong Kong Innovative Drug ETF include companies such as BeiGene, CanSino Biologics, and Innovent Biologics, with significant percentages of the fund's total assets allocated to these stocks [2] - The largest holding is BeiGene, accounting for 10.62% of the portfolio, followed closely by CanSino Biologics at 10.55% and Innovent Biologics at 10.21% [2] - Other notable holdings include China National Pharmaceutical Group and Stone Group, with respective allocations of 9.62% and 7.56% [2]